الفهرس 
Breast cancerOnly 14 pages are availabe for public view
 |  | from | 103 |  |  |
| | | from | 103 | | |
Abstract
This is a retrospective study that was conducted out on patients presenting to Clinical Oncology and Nuclear Medicine Department, Menoufia University from year 2018 to 2021, diagnosed as her-2 positive breast cancer and treated with adjuvant Trastuzumab (either IV or SC).
Our study included 187 Patients (186 females; Mean age 44.88±9.93years) classified according to route of administration into two groups: 88 for intravenous group and 99 for subcutaneous group.
There was no significant difference between two groups regard patient characteristics.
There was no significant difference between two groups regard disease characteristics.
There was no significant difference between two groups regard treatment received.
There was no significant difference between two groups regard
Cardiotoxicity.
There was no significant difference between two groups regard discontinuation of treatment due to trustuzumab inuced cardiotoxicity
There was no significant risk factor for trastuzumab induced cardiotoxicity except Anthracyclin cycles which was higher among pateints developed cardiotoxicity of subcutaneous treatment group (p value 0.045).
In this study, there is a significant difference between the two groups regarding progression, being more in IV group than SC one ((14.8%), (4.1%) respectively P value = 0.011), but no significant difference between the two groups regarding the type of progression. The prescription of either s.c. or i.v. trastuzumab in our study was based on availability and refundability and this may affect the progression.